{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:07:47Z","timestamp":1775822867413,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of bleomycin, etoposide, and cisplatin is the standard regimen for good-risk metastatic nonseminomatous germ cell tumors, with etoposide and cisplatin used when pulmonary risk is present. Etoposide and cisplatin therapy is generally well tolerated, and severe toxicities are particularly rare after the first standard-dose cycle. We report a case of early-onset, simultaneous multiorgan failure after a single cycle of etoposide and cisplatin therapy, successfully managed with etoposide\u2013carboplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 54-year-old Japanese man with stage IIa nonseminomatous germ cell tumor received a standard-dose first cycle of etoposide and cisplatin therapy (etoposide 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , cisplatin 20 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , days 1\u20135). Despite appropriate hydration, he developed hepatic dysfunction, severe diarrhea, ototoxicity, acute kidney injury requiring hemodialysis, pancytopenia, and visual impairment. Supportive therapy, including dialysis, corticosteroids, broad-spectrum antibiotics, and granulocyte colony-stimulating factor, was provided. Although renal function partially improved, the patient had persistent severe renal dysfunction consistent with Kidney Disease: Improving Global Outcomes stage 3 acute kidney injury, rendering further cisplatin therapy unsafe. He subsequently received three cycles of etoposide\u2013carboplatin (etoposide 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , days 1\u20135; carboplatin area under the curve 5), which were well tolerated. Tumor markers normalized, and imaging confirmed complete remission. At 12-month follow-up, he remained disease-free with stable renal function and improved general condition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that even a standard-dose, first-cycle etoposide and cisplatin regimen can trigger abrupt, life-threatening multiorgan toxicities affecting renal, hepatic, auditory, hematologic, and visual systems. Such early, simultaneous onset has rarely been described in scientific literature. When cisplatin continuation is unsafe, etoposide\u2013carboplatin may serve as a feasible alternative to achieve remission while minimizing systemic toxicity. Careful evaluation of patient-specific risk factors, including hypertension, renal reserve, and renin\u2013angiotensin system inhibitor use, is essential before initiating cisplatin-based therapy. This case highlights the importance of individualized treatment planning and prompt recognition of severe chemotherapy-induced toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-05894-3","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:35:15Z","timestamp":1772638515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe multiorgan toxicities after the first cycle of standard-dose etoposide\u2013cisplatin therapy for metastatic nonseminoma successfully managed with etoposide\u2013carboplatin: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-0137","authenticated-orcid":false,"given":"Takanori","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"5","key":"5894_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00003495-200666050-00005","volume":"66","author":"HG Kopp","year":"2006","unstructured":"Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, et al. Advances in the treatment of testicular cancer. Drugs. 2006;66(5):641\u201359.","journal-title":"Drugs"},{"issue":"7","key":"5894_CR2","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1200\/JCO.1997.15.7.2553","volume":"15","author":"H Xiao","year":"1997","unstructured":"Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol. 1997;15(7):2553\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5894_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1200\/JCO.1998.16.2.702","volume":"16","author":"SB Saxman","year":"1998","unstructured":"Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998;16(2):702\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5894_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000510384","volume":"99","author":"T Miyoshi","year":"2021","unstructured":"Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C. Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology. 2021;99(2):105\u201313.","journal-title":"Oncology"},{"issue":"14","key":"5894_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2174\/1389557519666190320124438","volume":"19","author":"NRA Ridzuan","year":"2019","unstructured":"Ridzuan NRA, Rashid NA, Othman F, Budin SB, Hussan F, Teoh SL. Protective role of natural products in cisplatin-induced nephrotoxicity. Mini Rev Med Chem. 2019;19(14):1134\u201343.","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"5894_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxics3030268","volume":"3","author":"A Callejo","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan ID, Llorens J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics. 2015;3(3):268\u201393.","journal-title":"Toxics"},{"key":"5894_CR7","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.ejps.2024.106939","volume":"203","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy EA, Saber S, Hamad RS, Abdel-Reheim MA, El-Kott AF, AlShehri MA, et al. Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies. Eur J Pharm Sci. 2024;203:106939.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"5894_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.1997.15.5.1844","volume":"15","author":"A Horwich","year":"1997","unstructured":"Horwich A, Sleijfer DT, Foss\u00e5 SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council\/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15(5):1844\u201352.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5894_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007.","journal-title":"Kidney Int"},{"key":"5894_CR10","unstructured":"Burns CV, Edwin SB, Szpunar S, Forman J. Cisplatin-induced nephrotoxicity in an outpatient setting."},{"issue":"19","key":"5894_CR11","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645\u201353.","journal-title":"Dalton Trans"},{"issue":"11","key":"5894_CR12","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","volume":"28","author":"M Chovanec","year":"2017","unstructured":"Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670\u20139.","journal-title":"Ann Oncol"},{"key":"5894_CR13","doi-asserted-by":"crossref","unstructured":"Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, et al. NCCN Guidelines\u00ae Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025;23(4).","DOI":"10.6004\/jnccn.2025.0018"},{"issue":"5","key":"5894_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/carcin\/15.5.845","volume":"15","author":"E Levy","year":"1994","unstructured":"Levy E, Baroche C, Barret JM, Alapetite C, Salles B, Averbeck D, et al. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis. 1994;15(5):845\u201350.","journal-title":"Carcinogenesis"},{"issue":"11","key":"5894_CR15","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490\u2013518.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"5894_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.etp.2008.09.003","volume":"61","author":"YI Chirino","year":"2009","unstructured":"Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009;61(3):223\u201342.","journal-title":"Exp Toxicol Pathol"},{"issue":"8","key":"5894_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","volume":"86","author":"NA dos Santos","year":"2012","unstructured":"dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012;86(8):1233\u201350.","journal-title":"Arch Toxicol"},{"key":"5894_CR18","doi-asserted-by":"publisher","first-page":"967826","DOI":"10.1155\/2014\/967826","volume":"2014","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826.","journal-title":"Biomed Res Int"},{"key":"5894_CR19","doi-asserted-by":"crossref","unstructured":"McSweeney KR, Gadanec LK, Qaradakhi T, Ali BA, Zulli A, Apostolopoulos V. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers (Basel). 2021;13(7).","DOI":"10.3390\/cancers13071572"},{"key":"5894_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fphar.2017.00196","volume":"8","author":"E Herrad\u00f3n","year":"2017","unstructured":"Herrad\u00f3n E, Gonz\u00e1lez C, Uranga JA, Abalo R, Mart\u00edn MI, L\u00f3pez-Miranda V. Characterization of cardiovascular alterations induced by different chronic cisplatin treatments. Front Pharmacol. 2017;8:196.","journal-title":"Front Pharmacol"},{"key":"5894_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3389\/fphar.2018.01111","volume":"9","author":"Z Zazuli","year":"2018","unstructured":"Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, et al. Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol. 2018;9:1111.","journal-title":"Front Pharmacol"},{"issue":"4","key":"5894_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396\u2013402.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"5894_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1483","volume":"106","author":"BI Dr\u00f6gem\u00f6ller","year":"2019","unstructured":"Dr\u00f6gem\u00f6ller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, et al. Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research. Clin Pharmacol Ther. 2019;106(2):350\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"5894_CR24","first-page":"032","volume":"4","author":"SL Garcia","year":"2020","unstructured":"Garcia SL, Lauritsen J, Zhang Z, Bandak M, Dalgaard MD, Nielsen RL, et al. Prediction of nephrotoxicity associated with cisplatin-based chemotherapy in testicular cancer patients. JNCI Cancer Spectr. 2020;4(3):032.","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"5894_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00000421-198906000-00010","volume":"12","author":"M Martin","year":"1989","unstructured":"Martin M, Diaz-Rubio E, Furi\u00f3 V, Bl\u00e1zquez J, Almenarez J, Fari\u00f1a J. Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Report of a case with necropsy study. Am J Clin Oncol. 1989;12(3):229\u201334.","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"5894_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jjco\/hyd103","volume":"30","author":"I Sekine","year":"2000","unstructured":"Sekine I, Matsuda T, Saisho T, Watanabe H, Yamamoto N, Kunitoh H, et al. Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity. Jpn J Clin Oncol. 2000;30(9):401\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"5894_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-6-1","volume":"6","author":"G Hofmann","year":"2006","unstructured":"Hofmann G, Bauernhofer T, Krippl P, Lang-Loidolt D, Horn S, Goessler W, et al. Plasmapheresis reverses all side-effects of a cisplatin overdose\u2014A case report and treatment recommendation. BMC Cancer. 2006;6:1.","journal-title":"BMC Cancer"},{"issue":"8","key":"5894_CR28","doi-asserted-by":"publisher","first-page":"e5850","DOI":"10.1097\/MD.0000000000005850","volume":"96","author":"H Cherniawsky","year":"2017","unstructured":"Cherniawsky H, Merchant N, Sawyer M, Ho M. A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin. Medicine (Baltimore). 2017;96(8):e5850.","journal-title":"Medicine (Baltimore)"},{"key":"5894_CR29","doi-asserted-by":"crossref","unstructured":"Tan AC, Marx GM. Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia. BMJ Case Rep. 2018;2018.","DOI":"10.1136\/bcr-2017-222948"},{"issue":"7","key":"5894_CR30","doi-asserted-by":"publisher","first-page":"e24695","DOI":"10.1097\/MD.0000000000024695","volume":"100","author":"Y Matsumoto","year":"2021","unstructured":"Matsumoto Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, et al. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis: a case report. Medicine (Baltimore). 2021;100(7):e24695.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"5894_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/ehjcr\/ytae365","volume":"8","author":"J ErquiciaPeralt","year":"2024","unstructured":"ErquiciaPeralt J, Fernandez Gonzalez L, Garcia San Rom\u00e1n K, Astorga Burgo JC, Ac\u00edn LA. An acute coronary syndrome in an unusual patient: analysing cisplatin toxicity\u2014A case report and review of the literature. Eur Heart J Case Rep. 2024;8(8):365.","journal-title":"Eur Heart J Case Rep"},{"key":"5894_CR32","doi-asserted-by":"crossref","unstructured":"Almutairi LA, Abdelghaffar EG, Hafney HA, Ebaid HM, Alkhodair SA, Shaalan AAM, et al. Protective impacts of chlorella vulgaris on cisplatin-induced toxicity in liver, kidney, and spleen of rats: role of oxidative stress, inflammation, and Nrf2 modulation. Life (Basel). 2025;15(6).","DOI":"10.3390\/life15060934"},{"key":"5894_CR33","doi-asserted-by":"publisher","first-page":"1809394","DOI":"10.1155\/2016\/1809394","volume":"2016","author":"J Paken","year":"2016","unstructured":"Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1809394.","journal-title":"J Toxicol"},{"key":"5894_CR34","doi-asserted-by":"publisher","first-page":"8851525","DOI":"10.1155\/2020\/8851525","volume":"2020","author":"N Zhang","year":"2020","unstructured":"Zhang N, Cai J, Xu L, Wang H, Liu W. Cisplatin-induced stria vascularis damage is associated with inflammation and fibrosis. Neural Plast. 2020;2020:8851525.","journal-title":"Neural Plast"},{"issue":"10","key":"5894_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0968-0004(00)89095-7","volume":"20","author":"DB Zamble","year":"1995","unstructured":"Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20(10):435\u20139.","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"5894_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2144\/fsoa-2022-0081","volume":"9","author":"A Bader","year":"2023","unstructured":"Bader A, Begemann M, Al-Obaidi A, Habib MH, Anwer F, Raza S. Ocular complications of antineoplastic therapies. Future Sci OA. 2023;9(7):871.","journal-title":"Future Sci OA"},{"issue":"3","key":"5894_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/s-2005-858020","volume":"222","author":"M Martin","year":"2005","unstructured":"Martin M, Weber-V\u00e1rszegi J, Flammer J. Toxic optic neuropathy due to cisplatin therapy: a case report. Klin Monbl Augenheilkd. 2005;222(3):244\u20137.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"5894_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/0268-960X(88)90032-X","volume":"2","author":"BH Chong","year":"1988","unstructured":"Chong BH. Heparin-induced thrombocytopenia. Blood Rev. 1988;2(2):108\u201314.","journal-title":"Blood Rev"},{"issue":"5","key":"5894_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/mco.2020.2127","volume":"13","author":"H Oda","year":"2020","unstructured":"Oda H, Mizuno T, Ikejiri M, Nakamura M, Tsunoda A, Ishihara M, et al. Risk factors for cisplatin-induced acute kidney injury: a pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice. Mol Clin Oncol. 2020;13(5):58.","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"5894_CR40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1177\/1078155219901305","volume":"26","author":"W Ben Ayed","year":"2020","unstructured":"Ben Ayed W, Ben Said A, Hamdi A, Mokrani A, Masmoudi Y, Toukabri I, et al. Toxicity, risk factors and management of cisplatin-induced toxicity: a prospective study. J Oncol Pharm Pract. 2020;26(7):1621\u20139.","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-05894-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:25:49Z","timestamp":1775820349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-05894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5894"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-05894-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}